{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:28:50Z","timestamp":1792056530624,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bethune Charitable Foundation of Pharmaceutical Research Capacity Building Project","award":["B-19-H-20200622"],"award-info":[{"award-number":["B-19-H-20200622"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00210-024-03419-7","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T09:02:24Z","timestamp":1725958944000},"page":"2717-2727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study"],"prefix":"10.1007","volume":"398","author":[{"given":"Chaoqun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"3419_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5883","volume":"11","author":"T Balfousias","year":"2019","unstructured":"Balfousias T, Apostolopoulos AP, Angelis S et al (2019) Spontaneous knee hemarthrosis due to hypofibrinogenemia following tigecycline treatment for periprosthetic joint infection. Cureus 11:e5883. https:\/\/doi.org\/10.7759\/cureus.5883","journal-title":"Cureus"},{"key":"3419_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/10408347.2020.1793098","volume":"52","author":"M Bialkower","year":"2022","unstructured":"Bialkower M, Garnier G (2022) Fibrinogen diagnostics in major hemorrhage. Crit Rev Anal Chem 52:194\u2013209. https:\/\/doi.org\/10.1080\/10408347.2020.1793098","journal-title":"Crit Rev Anal Chem"},{"key":"3419_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/antibiotics9020084","volume":"9","author":"A Brandtner","year":"2020","unstructured":"Brandtner A, Bachler M, Fries D et al (2020) Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system. Antibiotics 9:84. https:\/\/doi.org\/10.3390\/antibiotics9020084","journal-title":"Antibiotics"},{"key":"3419_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijantimicag.2009.01.015","volume":"34","author":"O Burkhardt","year":"2009","unstructured":"Burkhardt O, Rauch K, Kaever V et al (2009) Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 34:101\u2013102. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.01.015","journal-title":"Int J Antimicrob Agents"},{"key":"3419_CR5","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","volume":"42","author":"D Campany-Herrero","year":"2020","unstructured":"Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P et al (2020) Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm 42:1184\u20131189. https:\/\/doi.org\/10.1007\/s11096-020-01072-7","journal-title":"Int J Clin Pharm"},{"key":"3419_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/jth.14216","volume":"16","author":"A Casini","year":"2018","unstructured":"Casini A, Undas A, Palla R et al (2018) Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost JTH 16:1887\u20131890. https:\/\/doi.org\/10.1111\/jth.14216","journal-title":"J Thromb Haemost JTH"},{"key":"3419_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11096-019-00912-5","volume":"41","author":"N Cui","year":"2019","unstructured":"Cui N, Cai H, Li Z et al (2019) Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm 41:1408\u20131413. https:\/\/doi.org\/10.1007\/s11096-019-00912-5","journal-title":"Int J Clin Pharm"},{"key":"3419_CR8","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y (2019) Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis off Publ Infect Dis Soc Am 69:S565\u2013S575. https:\/\/doi.org\/10.1093\/cid\/ciz830","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"key":"3419_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022638","volume":"99","author":"Q Fan","year":"2020","unstructured":"Fan Q, Huang W, Weng Y et al (2020) Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine (Baltimore) 99:e22638. https:\/\/doi.org\/10.1097\/MD.0000000000022638","journal-title":"Medicine (Baltimore)"},{"key":"3419_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","volume":"52","author":"TR Fritsche","year":"2005","unstructured":"Fritsche TR, Sader HS, Stilwell MG et al (2005) Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52:187\u2013193. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2005.05.004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3419_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009961","volume":"97","author":"T-T Geng","year":"2018","unstructured":"Geng T-T, Xu X, Huang M (2018) High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine (Baltimore) 97:e9961. https:\/\/doi.org\/10.1097\/MD.0000000000009961","journal-title":"Medicine (Baltimore)"},{"key":"3419_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","volume":"20","author":"M Guo","year":"2022","unstructured":"Guo M, Liang J, Li D et al (2022) Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J 20:12. https:\/\/doi.org\/10.1186\/s12959-022-00369-z","journal-title":"Thromb J"},{"key":"3419_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","volume":"76","author":"J Hu","year":"2020","unstructured":"Hu J, Xiao Y, Zheng Y et al (2020) Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol 76:913\u2013922. https:\/\/doi.org\/10.1007\/s00228-020-02860-w","journal-title":"Eur J Clin Pharmacol"},{"key":"3419_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","volume":"35","author":"K Kadoyama","year":"2012","unstructured":"Kadoyama K, Sakaeda T, Tamon A, Okuno Y (2012) Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull 35:967\u2013970. https:\/\/doi.org\/10.1248\/bpb.35.967","journal-title":"Biol Pharm Bull"},{"key":"3419_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/0091270011416938","volume":"52","author":"JM Korth-Bradley","year":"2012","unstructured":"Korth-Bradley JM, Troy SM, Matschke K et al (2012) Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol 52:1379\u20131387. https:\/\/doi.org\/10.1177\/0091270011416938","journal-title":"J Clin Pharmacol"},{"key":"3419_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.943674","volume":"13","author":"B Leng","year":"2022","unstructured":"Leng B, Shen C, Gao T et al (2022) Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China. Front Pharmacol 13:943674. https:\/\/doi.org\/10.3389\/fphar.2022.943674","journal-title":"Front Pharmacol"},{"key":"3419_CR17","doi-asserted-by":"publisher","DOI":"10.5414\/CP204337","author":"ZK Li","year":"2023","unstructured":"Li ZK, Zheng P (2023) Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: a case report. Int J Clin Pharmacol Ther. https:\/\/doi.org\/10.5414\/CP204337","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3419_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F (2021) Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag 17:325\u2013332. https:\/\/doi.org\/10.2147\/TCRM.S302850","journal-title":"Ther Clin Risk Manag"},{"key":"3419_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","volume":"47","author":"W Ni","year":"2016","unstructured":"Ni W, Han Y, Zhao J et al (2016) Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 47:107\u2013116. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.11.011","journal-title":"Int J Antimicrob Agents"},{"key":"3419_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","volume":"89","author":"H Pieringer","year":"2010","unstructured":"Pieringer H, Schmekal B, Biesenbach G, Pohanka E (2010) Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol 89:1063\u20131064. https:\/\/doi.org\/10.1007\/s00277-010-0911-7","journal-title":"Ann Hematol"},{"key":"3419_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.healthpol.2011.10.001","volume":"104","author":"C Quintal","year":"2012","unstructured":"Quintal C, Mendes P (2012) Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy Amst Neth 104:61\u201368. https:\/\/doi.org\/10.1016\/j.healthpol.2011.10.001","journal-title":"Health Policy Amst Neth"},{"key":"3419_CR22","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1128\/AAC.01232-12","volume":"57","author":"J Ramirez","year":"2013","unstructured":"Ramirez J, Dartois N, Gandjini H et al (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:1756\u20131762. https:\/\/doi.org\/10.1128\/AAC.01232-12","journal-title":"Antimicrob Agents Chemother"},{"key":"3419_CR23","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/CMR.00079-17","volume":"31","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2018","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Guti\u00e9rrez-Guti\u00e9rrez B, Machuca I, Pascual A (2018) Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Clin Microbiol Rev 31:e00079-e117. https:\/\/doi.org\/10.1128\/CMR.00079-17","journal-title":"Clin Microbiol Rev"},{"key":"3419_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","volume":"26","author":"WE Rose","year":"2006","unstructured":"Rose WE, Rybak MJ (2006) Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 26:1099\u20131110. https:\/\/doi.org\/10.1592\/phco.26.8.1099","journal-title":"Pharmacotherapy"},{"key":"3419_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","volume":"47","author":"N Sabanis","year":"2015","unstructured":"Sabanis N, Paschou E, Gavriilaki E et al (2015) Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis Lond Engl 47:743\u2013746. https:\/\/doi.org\/10.3109\/23744235.2015.1043942","journal-title":"Infect Dis Lond Engl"},{"key":"3419_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/08923970902838672","volume":"31","author":"R Saliba","year":"2009","unstructured":"Saliba R, Paasch L, El Solh A (2009) Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol 31:583\u2013588. https:\/\/doi.org\/10.3109\/08923970902838672","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"3419_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","volume":"39","author":"F Shen","year":"2015","unstructured":"Shen F, Han Q, Xie D et al (2015) Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis 39:25\u201333. https:\/\/doi.org\/10.1016\/j.ijid.2015.08.009","journal-title":"Int J Infect Dis"},{"key":"3419_CR28","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.3390\/jcm10204702","volume":"10","author":"B Treml","year":"2021","unstructured":"Treml B, Rajsic S, Hell T et al (2021) Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis. J Clin Med 10:4702. https:\/\/doi.org\/10.3390\/jcm10204702","journal-title":"J Clin Med"},{"key":"3419_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/antibiotics9030109","volume":"9","author":"H Van der Weide","year":"2020","unstructured":"Van der Weide H, Ten Kate MT, Vermeulen-de Jongh DMC et al (2020) Successful high-dosage monotherapy of tigecycline in a multidrug-resistant Klebsiella pneumoniae pneumonia-septicemia model in rats. Antibiot Basel Switz 9:109. https:\/\/doi.org\/10.3390\/antibiotics9030109","journal-title":"Antibiot Basel Switz"},{"key":"3419_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1159\/000525380","volume":"107","author":"D Wang","year":"2022","unstructured":"Wang D, Lin C, Gu C et al (2022) Tigecycline-associated coagulopathy: a single-center retrospective analysis. Pharmacology 107:524\u2013536. https:\/\/doi.org\/10.1159\/000525380","journal-title":"Pharmacology"},{"key":"3419_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.idcr.2018.01.003","volume":"11","author":"P-C Wu","year":"2018","unstructured":"Wu P-C, Wu C-C (2018) Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. Idcases 11:56\u201357. https:\/\/doi.org\/10.1016\/j.idcr.2018.01.003","journal-title":"Idcases"},{"key":"3419_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009124","volume":"96","author":"X Wu","year":"2017","unstructured":"Wu X, Zhao P, Dong L, Zhang X (2017) A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine (Baltimore) 96:e9124. https:\/\/doi.org\/10.1097\/MD.0000000000009124","journal-title":"Medicine (Baltimore)"},{"key":"3419_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/hpm.3429","volume":"37","author":"Y Yang","year":"2022","unstructured":"Yang Y, Hu R, Geng X et al (2022) The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China. Int J Health Plann Manage 37:1650\u20131662. https:\/\/doi.org\/10.1002\/hpm.3429","journal-title":"Int J Health Plann Manage"},{"key":"3419_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4274\/tjh.2017.0310","volume":"35","author":"F Y\u0131lmaz Duran","year":"2018","unstructured":"Y\u0131lmaz Duran F, Y\u0131ld\u0131r\u0131m H, \u015een EM (2018) A lesser known side effect of tigecycline: hypofibrinogenemia. Turk J Haematol off J Turk Soc Haematol 35:83\u201384. https:\/\/doi.org\/10.4274\/tjh.2017.0310","journal-title":"Turk J Haematol off J Turk Soc Haematol"},{"key":"3419_CR35","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","volume":"45","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang J, Liu H et al (2020) Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther 45:1434\u20131441. https:\/\/doi.org\/10.1111\/jcpt.13250","journal-title":"J Clin Pharm Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03419-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03419-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:44:42Z","timestamp":1742294682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03419-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03419-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Medical Ethics Committee of Peking University People\u2019s Hospital (Beijing, China, IRB number 2023PHB294-001). Written informed consent from the participants\u2019 legal guardian\/next of kin was not required to participate in this retrospective study in accordance with the national legislation and the institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We confirm that we have read the journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The full article was not posted or published elsewhere.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}